Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/QAD.0000000000002688 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Real-world efficacy of bictegravir/emtricitabine/tenofovir alafenamide regimen in patients infected with HIV-1 sub-subtype A6 harbouring the L74I mutation.
HIV Med
September 2025
Moscow Regional AIDS Center, Moscow Region, Kotelniki, Russia.
Objectives: This study aimed to evaluate the effectiveness of bictegravir (BIC)-based antiretroviral therapy (ART) against HIV-1 sub-subtype A6 viruses carrying the L74I polymorphic mutation in integrase.
Methods: A total of 100 ART-naive people living with HIV from the Moscow Regional AIDS Center were enrolled between May and July 2023. HIV-1 subtypes and baseline drug resistance mutations were analysed prior to treatment initiation.
Bictegravir, emtricitabine, and tenofovir alafenamide versus ritonavir-boosted protease inhibitor-based antiretroviral therapy in people with HIV and viral suppression on second-line therapy in Haiti: an open-label, randomised, non-inferiority trial.
Lancet HIV
September 2025
Harvard Medical School, Boston, MA, USA; Brigham and Women's Hospital, Boston, MA, USA. Electronic address:
Background: Patients on second-line protease inhibitor-based regimens in low-income and middle-income countries have high rates of nucleoside reverse transcriptase inhibitor (NRTI) resistance, but access to testing is scarce. We aimed to assess the efficacy of combination oral bictegravir, emtricitabine, and tenofovir alafenamide in this population.
Methods: In this open-label non-inferiority trial conducted in Port-au-Prince, Haiti, adults (aged 18 years or older) with viral suppression (HIV-1 RNA <200 copies per mL) on second-line regimens including ritonavir-boosted protease inhibitors and two NRTIs were randomised (1:1) using a computer-generated random-number list.
Mapping the Gut Microbiota Composition in the Context of Raltegravir, Dolutegravir, and Bictegravir-A Scoping Review.
Int J Mol Sci
July 2025
National Institute of Haematology and Infectious Diseases, Central Hospital of Southern Pest, H-1097 Budapest, Hungary.
(1) Background: Second-generation integrase strand transfer inhibitors (INSTIs) are now the preferred first-line therapies for human immunodeficiency virus (HIV). However, concerns regarding their side effects, such as weight gain and metabolic disturbances, have emerged. This scoping review aims to assess the effects of INSTIs on the gut microbiota, with a focus on differences between agents and their clinical implications.
View Article and Find Full Text PDFAssociations between weight gain, integrase inhibitors antiretroviral agents, and gut microbiome in people living with HIV: a cross-sectional study.
Sci Rep
July 2025
Metabolism and Nutrition Research Group (MNUT), Louvain Drug Research Institute (LDRI), UCLouvain, Université Catholique de Louvain, Brussels, Belgium.
Dolutegravir and bictegravir are second-generation HIV integrase strand transfer inhibitors (INSTIs) that were previously associated with abnormal weight gain. This monocentric cross-sectional study investigates associations between weight gain during the first year after initiation of dolutegravir, bictegravir or other anchor drugs and gut microbiome diversity as well as taxa composition. The study enrolled 79 participants receiving dolutegravir, 32 receiving bictegravir and 10 receiving non-INSTI based regimens.
View Article and Find Full Text PDFDo we need routine integrase resistance testing before starting antiretroviral therapy?
Lancet HIV
September 2025
Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, USA; Harvard Medical School, Boston, MA, USA.
Oral second-generation integrase strand transfer inhibitors are now anchor drugs of antiretroviral therapy (ART) globally due to their high resistance barriers. In high-income settings, guidelines recommend routine protease and reverse transcriptase resistance testing before ART initiation but suggest routine integrase resistance testing only for individuals at elevated risk of integrase resistance. Improved characterisation of transmitted integrase resistance, its detection, and its clinical impact will guide future recommendations for clinical decision making.
View Article and Find Full Text PDF